JMP Advances Life Sciences Analysis in New Releases

JMP Advances Life Sciences Analysis in New Releases
JMP® Genomics adds linkage maps; JMP® Clinical automates creation of patient narratives

CARY, N.C.--(BUSINESS WIRE)--Life scientists gain new and enhanced visual data exploration and analysis capabilities with new releases of JMP Genomics and JMP Clinical software by SAS, the leader in business analytics. Both solutions, announced today, dynamically link SAS® Analytics and JMP graphics to provide a comprehensive picture of research results.

"JMP Clinical doesn't replace the statistician or the SAS programs"
.JMP Genomics 5.1 adds a suite of new tools for constructing and visualizing linkage maps, used to improve agronomic crops and in animal breeding programs. JMP Clinical 3.1 automates the creation of patient narratives for each subject in a clinical trial who experiences a serious adverse event. The software saves the narratives as a Rich Text Format (RTF) file for further configuration and inclusion in the Clinical Study Report.

In addition, the new JMP Genomics release includes:


  • Import routines for standard data formats (e.g., BAM, VCF).
  • Several new methods for analysis and summarization of rare variants across loci or pathways.
  • Normalization and analysis routines tailored for count data.

JMP developed the linkage mapping tools in response to a request by scientists with the US Department of Agriculture's Agricultural Research Service (USDA-ARS). Eric Jackson, PhD, an award-winning USDA-ARS research molecular biologist and JMP Genomics user, leads the Collaborative Oat Research Enterprise, a global research partnership of scientists, growers and millers dedicated to improving oat nutrition through genomics. The new capabilities save time by calling SAS algorithms to order markers along a genome, said Jackson, who recently was recognized by the USDA-ARS as an Outstanding Early Career Research Scientist "for revitalizing oat genomics research ... through exceptional scientific creativity and partnerships."


In addition to the automated patient narratives, JMP Clinical 3.1 also:


  • Instantly generates patient profiles from CDISC data and saves them as a PDF for submission to the US Food and Drug Administration.
  • Utilizes multiple testing methods, such as the double false discovery rate procedure, to mitigate the risk of over-reporting adverse events.

"JMP Clinical doesn't replace the statistician or the SAS programs," says Mark Williams, Vice President and CIO of Applied Clinical Intelligence, a contract research organization serving the pharmaceutical, biotechnology, medical device and health care industries. Rather, it "bridges the clinical-statistical divide."

About JMP

JMP is a business unit of SAS, established in 1989 to create interactive software for desktop discovery analytics. John Sall, SAS co-founder and Executive Vice President, also heads the JMP business unit.

About SAS

SAS is the leader in business analytics software and services, and the largest independent vendor in the business intelligence market. Through innovative solutions delivered within an integrated framework, SAS helps customers at more than 50,000 sites improve performance and deliver value by making better decisions faster. Since 1976 SAS has been giving customers around the world THE POWER TO KNOW®.

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.